Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/198337
Title: Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients
Author: Martínez Casanova, Javier
Esteve Pitarch, Erika
Colom Codina, Helena
Gumucio Sanguino, Víctor Daniel
Cobo Sacristán, Sara
Shaw, Evelyn
Maisterra Santos, Kristel
Sabater Riera, Joan
Pérez Fernandez, Xosé L.
Rigo Bonnin, Raül
Tubau Quintano, Fe
Carratalà, Jordi
Padullés Zamora, Ariadna
Keywords: Antibiòtics betalactàmics
Farmacocinètica
Farmacovigilància
Beta lactam antibiotics
Pharmacokinetics
Drug monitoring
Issue Date: 7-Mar-2023
Publisher: MDPI AG
Abstract: Critically ill patients undergo significant pathophysiological changes that affect antibiotic pharmacokinetics. Piperacillin/tazobactam administered by continuous infusion (CI) improves pharmacokinetic/pharmacodynamic (PK/PD) target attainment. This study aimed to characterize piperacillin PK after CI administration of piperacillin/tazobactam in critically ill adult patients with preserved renal function and to determine the empirical optimal dosing regimen. A total of 218 piperacillin concentrations from 106 patients were simultaneously analyzed through the population PK approach. A two-compartment linear model best described the data. Creatinine clearance (CLCR) estimated by CKD-EPI was the covariate, the most predictive factor of piperacillin clearance (CL) interindividual variability. The mean (relative standard error) parameter estimates for the final model were: CL: 12.0 L/h (6.03%); central and peripheral compartment distribution volumes: 20.7 L (8.94%) and 62.4 L (50.80%), respectively; intercompartmental clearance: 4.8 L/h (26.4%). For the PK/PD target of 100% fT(>1xMIC), 12 g of piperacillin provide a probability of target attainment > 90% for MIC < 16 mg/L, regardless of CLCR, but higher doses are needed for MIC = 16 mg/L when CLCR > 100 mL/min. For 100% fT(>4xMIC), the highest dose (24 g/24 h) was not sufficient to ensure adequate exposure, except for MICs of 1 and 4 mg/L. Our model can be used as a support tool for initial dose guidance and during therapeutic drug monitoring.
Note: Reproducció del document publicat a: https://doi.org/10.3390/antibiotics12030531
It is part of: Antibiotics, 2023, vol. 12, num. 3, p. 531
URI: http://hdl.handle.net/2445/198337
Related resource: https://doi.org/10.3390/antibiotics12030531
ISSN: 2079-6382
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
antibiotics-12-00531.pdf3.35 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons